DividendAugust 12, 2026

Dividend Win Wednesday: Insiders Buy While a 90% Drawdown Trades at 820% Upside

Top 5 Pixie Picks

This Week's Setup

Greed reads 63 on the Fear & Greed index while the S&P 500 CAPE sits at 38.9, a valuation level that has historically preceded multi-year mean reversion. Within that backdrop, the dividend screen is flagging six names trading 9–19% off their 52-week highs with free cash flow yields between 4.6% and 14.2%, and one semiconductor capital equipment name down 90% that analysts believe is worth 9× the current price.

Insiders are active across energy, pharma, and healthcare, with ten separate Form 4 filings in the last 30 days showing both modest selling at energy producers and persistent buying at biotech and managed care names. Payout ratios on the top four names range from 15.7% to 64.7%, leaving meaningful reinvestment room even as yields sit between 0.9% and 3.1%.

Quick Scan

#	Ticker	One-line thesis
1	COP	Energy at 4.8% FCF yield, 9% drawdown, insider adds
2	NVS	Swiss pharma growing 9.6% with 3.1% yield coverage
3	NEM	Gold miner at 12.8% drawdown, 5.8% FCF yield
4	EOG	71.7bp earnings yield, 28× interest coverage, insider sells
5	BIIB	Near highs, 6.5% FCF yield, ten insider buys
6	CI	41.6% earnings yield, 19% drawdown, triple insider adds
7	KLAC	90% drawdown, 14.2% FCF yield, 820% analyst upside
8	GILD	HIV/oncology at 14% drawdown, 5.7% FCF yield, insider adds

The 8 Names

1. ConocoPhillips (COP)

Dividend yield: 2.7% | Payout ratio: 51.3% | 52w drawdown: 8.6%

The setup here is a 4.79% free cash flow yield with 11.3× interest coverage and a 0.73× net debt to EBITDA ratio, pairing energy exposure with a balance sheet that can weather commodity swings. Revenue grew 7.7% year over year while return on invested capital sits at 13.5%, a rate that sustains the 2.7% dividend while leaving half of free cash flow for buybacks or debt reduction.

Three insiders filed Form 4 transactions between July 17 and July 27, with Silvina Vatnick executing two separate periods and Ricardo Jaramillo Mejia one. UBS raised its price target to $153 from $143 on August 5, implying 23% upside from the $124.24 close, while BMO lifted its target to $135 and maintained Outperform.

The 8.6% drawdown is mild by energy sector standards, and the stock has been range-bound over the trailing year with a 0.15% trend coefficient. If crude prices revert below $70 WTI, the free cash flow yield compresses and the dividend payout ratio rises above 60%, tightening the margin for capital return.

2. Novartis AG (NVS)

Dividend yield: 3.1% | Payout ratio: 64.7% | 52w drawdown: 8.9%

Novartis delivers a 5.14% free cash flow yield with 16.0% return on invested capital and 9.6% year-over-year revenue growth, a combination that funds a 3.1% dividend while maintaining 15.3× interest coverage. The 64.7% payout ratio is covered by operating cash generation in a business with 75.8% gross margins, and the dividend has compounded at 7.2% annually over the past five years.

The stock trades at 7.7× book value with a negative 10-year earnings yield spread of 19 basis points, reflecting the market's willingness to pay a premium for pharmaceutical cash flows in a zero-real-rate environment. Analysts now see the stock as fully valued, with a consensus target of $153.87 sitting 1% below the $155.38 close.

Short interest is negligible at 0.2% of float, but the 8.9% drawdown and flat 12-month price trend signal that investors are waiting for the next clinical catalyst to justify moving the multiple higher from its current 22.3× earnings.

3. Newmont Corporation (NEM)

Dividend yield: 0.9% | Payout ratio: 15.7% | 52w drawdown: 12.8%

The 5.81% free cash flow yield sits against a 15.7% payout ratio, leaving 84% of cash generation available for debt reduction, buybacks, or organic growth in a business with 29.9% return on invested capital. Revenue jumped 21.3% year over year while the company carries negative 0.20× net debt to EBITDA, meaning it holds more cash than debt on an EBITDA-adjusted basis.

Three insiders sold shares between July 29 and August 5, with Peter Toth, Mark Rodgers, and Brian Tabolt each filing separate dispositions totaling 18,394 net shares. TD Cowen raised its price target to $133 from $127 on a Buy rating, sitting 13% above the $117.68 close, while the broader analyst consensus implies 21.4% upside to $142.82.

The 0.9% dividend yield is the lowest on this screen, a deliberate capital allocation choice that prioritizes reinvestment in a sector where production growth and cost control drive returns more than income. If gold prices plateau below $2,400 per ounce, the 12.8% drawdown extends and the valuation at 15.3× earnings offers limited downside cushion.

4. EOG Resources, Inc. (EOG)

Dividend yield: 2.9% | Payout ratio: 43.6% | 52w drawdown: 6.7%

EOG delivers a 71.7 basis point earnings yield with 28.1× interest coverage and a 4.57% free cash flow yield, while maintaining a 0.35× net debt to EBITDA ratio that ranks among the cleanest in the independent producer universe. Return on invested capital is 15.2%, and the 63.4% gross margin provides operating leverage if commodity prices stabilize above current levels.

Revenue declined 3.4% year over year, reflecting lower realized prices and modest production declines in certain basins. The 10-year normalized earnings yield of 248 basis points is strong, but the stock's 0.13% trailing-year trend coefficient shows it has essentially moved sideways over the past twelve months.

Three insiders sold shares in the first week of August, with Christopher Gaut, Charles Crisp, and Janet Clark each filing Form 4 dispositions totaling 14,343 net shares. Bernstein adjusted its price target to $156 from $155 while maintaining Market Perform, implying 10% upside from the $141.77 close, and the broader analyst consensus sits at $160.25 for 13% upside.

5. Biogen Inc. (BIIB)

Dividend yield: n/a | Payout ratio: 0.0% | 52w drawdown: 0.9%

The stock trades 0.9% off its 52-week high with a 6.53% free cash flow yield and 7.0% return on invested capital, while revenue grew 2.2% year over year in a mature neurology franchise. The company pays no dividend, directing 100% of free cash flow to debt reduction, pipeline investment, or opportunistic buybacks, and maintains 6.8× interest coverage with a 0.64× net debt to EBITDA ratio.

Lloyd Minor filed a Form 4 buy on August 5, marking the tenth insider purchase in the trailing six months with a net addition of three shares across all insiders. HSBC raised its price target to $165 from $157 but kept a Reduce rating, while the broader analyst consensus implies 7.5% upside to $219.44 from the $204.21 close.

The absence of a dividend means total return depends entirely on capital appreciation in a competitive Alzheimer's and multiple sclerosis landscape. Short interest is 3.2% of float, and the 75.7% gross margin is offset by a 0.13% negative 10-year earnings yield spread, signaling that the market has priced in pipeline execution risk.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

6. The Cigna Group (CI)

Dividend yield: 2.3% | Payout ratio: 27.7% | 52w drawdown: 19.3%

Cigna trades at a 41.6% earnings yield with an 11.6% free cash flow yield, a valuation dislocation that implies the market is pricing in meaningful multiple compression or earnings headwinds. Revenue grew 11.7% year over year with 11.2% return on invested capital, and the company maintains 6.5× interest coverage while carrying 1.72× net debt to EBITDA.

Three insiders added shares between July 24 and August 6, with James Lee filing two separate buys and Nicole Jones one, totaling three distinct Form 4 transactions. Analysts see 24.9% upside to a $341.50 consensus target, and the 2.3% dividend is covered nearly four times by free cash flow at the current 27.7% payout ratio.

The 19.3% drawdown and 2.4× price-to-earnings ratio flag either a deep value opportunity or a structural shift in managed care economics that the model cannot yet quantify. The stock has been flat over the trailing year with a -0.003% trend coefficient, and 2.3% short interest suggests modest skepticism but no crowded positioning.

7. KLA Corporation (KLAC)

Dividend yield: 4.6% | Payout ratio: 29.6% | 52w drawdown: 90.2%

KLA trades at a 14.21% free cash flow yield with a 66.5% return on invested capital, a 17.52% earnings yield, and 23.9% year-over-year revenue growth, yet the stock sits 90.2% below its 52-week high at $201.51. Analysts assign an $1,855.14 consensus price target, implying 820.6% upside, a spread that reflects either catastrophic model failure or a market pricing in terminal demand collapse for semiconductor capital equipment.

Three insiders added shares between August 5 and August 11, with Virendra Kirloskar filing two separate buys and Mary Beth Wilkinson one. The company raised its dividend following strong earnings, and Intel's $20 billion capital equipment offering is expected to benefit KLA's wafer inspection and process control franchise.

The 90.2% drawdown is the defining risk. Either the stock is the most mispriced name in the semiconductor supply chain or the market sees structural headwinds in logic and memory capital intensity that will compress margins and revenue for years. Short interest is 2.6% of float, and the -0.07% trailing-year trend coefficient shows the decline has been persistent, not a single-event capitulation.

8. Gilead Sciences, Inc. (GILD)

Dividend yield: 2.4% | Payout ratio: 47.9% | 52w drawdown: 14.4%

The 5.66% free cash flow yield pairs with a 24.4% return on invested capital and 78.8% gross margin in a diversified HIV, oncology, and liver disease franchise. Revenue grew 2.4% year over year, and the company maintains 10.6× interest coverage with a 0.84× net debt to EBITDA ratio, while the 2.4% dividend is covered twice by free cash flow at the current 47.9% payout.

Three insiders added shares between July 16 and August 11, with Andrew Dickinson, Johanna Mercier, and Keeley Cain Wettan each filing separate Form 4 transactions. MacroGenics announced a $10 million milestone following Gilead's exercise of an option to license a preclinical bispecific program, and analysts see 17.2% upside to a $157.83 consensus target.

The 14.4% drawdown and 0.07% trailing-year trend coefficient show the stock has underperformed in a year when biotech multiples expanded. Short interest is 1.9% of float, and the 10-year normalized earnings yield spread of 77 basis points is the narrowest on this screen, signaling limited valuation cushion if the HIV franchise faces biosimilar pressure or the oncology pipeline stalls.

What to Watch

• August 15: EOG Resources posts Q2 results; watch for production guidance and free cash flow generation relative to the 4.57% yield and 43.6% payout ratio in a flat WTI environment.

• August 19: Cigna reports earnings; the 41.6% earnings yield and 19.3% drawdown hinge on whether medical cost trends justify the current 2.4× P/E or force analysts to cut the $341.50 consensus target.

• August 28: Gilead updates investors on HIV market share and oncology pipeline progress; insider buying and a 14.4% drawdown depend on pipeline catalysts to justify the $157.83 analyst target.

• September FOMC: If the Fed signals a pause after two consecutive rate cuts, the dividend yield spread compresses and names trading at deep discounts face multiple re-rating risk.

Go Deeper

The dividend screener ranks stocks by sustainable yield, payout coverage, and valuation quality across sectors.
Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

Or start with the free Market Brief Digest

Where the market stands before the open, in plain language, every trading day. No account needed.

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.